Skip to Content
A home for paediatricians. A voice for children and youth.
CPS

Managing critical drug shortages in clinical practice

Posted: Dec 1, 2022


The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our copyright policy.

Principal author(s)

Derek McCreath, Geert ‘t Jong, Yaron Finkelstein, Charlotte Moore Hepburn, Canadian Paediatric Society, Drug Therapy Committee

Introduction

Drug shortages are a complex medical, social, and political problem with significant negative impacts on clinical practice in Canada. On March 17, 2017, amendments to the Food and Drug Regulations came into force mandating that market authorization holders must publicly report both drug shortages and discontinuations to a third-party website [1]. Since the enactment of this legislation, over 18,000 shortages and discontinuations have been documented [2]. In late summer 2022, critical shortages of liquid formulations of over-the-counter pain relievers and antipyretics were reported, garnering significant media attention, alarming families, and challenging health care systems. Weeks later, shortages of liquid formulations of antibiotics commonly used in paediatric practice were classified as Tier 3 drug shortages. Tier 3 drug shortages have the greatest potential impact on Canada’s drug supply and health care system. 

There are multiple reasons for these drug shortages, including complex supply chain issues, labour-related challenges, and a lack of both manufacturing capacity and emergency stock in the face of increased demand.  

Current critical drug shortages are anticipated to last several months, and new supply challenges may emerge as prescribers pivot to second- and third-line drugs. These serious drug shortages highlight both short-and long-term priorities for Canada’s health care providers and policy-makers, which include: 1. the need to ensure that prescribing practices align with the best available evidence; and 2. the need to proactively establish a safe, stable, and secure supply of the medications most necessary to treat children in Canada.

Prescribing according to best evidence

Resource-sensitive prescribing can optimize care and, simultaneously, conserve vital supply. Current best evidence supports the following prescribing principles:

1. Most acute respiratory illnesses are viral and do not require antibiotics. Patients presenting with viral syndromes should not be prescribed antibiotics. Choosing Wisely Canada has developed provider and patient education materials to support appropriate prescribing. Their resources include viral prescription pads (including one designed for treating children aged 6 months and over), family-centred advice in multiple languages on delayed prescribing (to encourage supportive care before filling an antibiotics prescription), and educational posters suitable for waiting rooms.

2. While modest evidence exists to support the use of macrolide antibiotics for an anti-inflammatory effect in very specific clinical circumstances [3][4], there is no evidence that macrolides play a significant role in moderating inflammation in uncomplicated paediatric respiratory illnesses. Young patients presenting with uncomplicated upper or lower respiratory illnesses (including asthma exacerbations) should not be prescribed macrolides for their anti-inflammatory properties. Macrolides are indicated when treating an infection caused by an atypical organism (e.g., Mycoplasma pneumoniae, Chlamydia pneumoniae, Chlamydia trachomatis) or when treating children with common bacterial infections and a life-threatening beta-lactam allergy.

3. Virtual care increased significantly during the pandemic [5][6]. While considered safe and effective in many clinical circumstances, scenarios remain where virtual care is inappropriate. Acute otitis media, pneumonia, Group A streptococcal (GAS) pharyngitis, and most urinary tract infections cannot be reliably diagnosed without a physical exam and, in some cases, a confirmatory laboratory test. With rare exception, patients should not be prescribed antibiotics for these clinical conditions based solely on a virtual encounter. As much as possible, providers should ensure that patients have access to in-person, ambulatory care when presenting with symptoms concerning for a bacterial infection.

4. When prescribing antibiotics, the shortest possible evidence-based effective course should be selected. Resource-sensitive prescribing will optimize patient outcomes by avoiding unnecessary (or unnecessarily long) antibiotic exposure, mitigate the surge of resistant bacterial strains, and conserve vital supply. See Table 1 [7]-[11] for an overview of antibiotic choices, doses, and durations for common paediatric infections. Local resistance patterns should be considered when prescribing.

Indication Antibiotics and dosage form available Recommended dose Recommended duration

Uncomplicated community-acquired pneumonia [7]

First line: Amoxicillin

Capsules: 250 mg, 500 mg

20–30 mg/kg/dose by mouth, three times daily

Maximum: 500 mg/dose

Consider rounding dose to the nearest capsule size

5 days (8)

Second line: Amoxicillin/Clavulanate

Tablets: 500/125 mg, 875/125 mg

Dose based on amoxicillin component

20–30 mg/kg/dose by mouth, three times daily

Maximum: 500 mg/dose

Consider rounding dose to the nearest quarter, half, or full tablet

Penicillin-allergic (non-life-threatening):

Cefprozil OR Cefuroxime

Tablets: 250 mg, 500 mg

15 mg/kg/dose by mouth, two times daily

Maximum: 500 mg/dose

Consider rounding dose to the nearest half or full tablet

Penicillin-allergic (life-threatening) or suspected atypical pneumonia:

Option #1: Clarithromycin

Tablets: 250 mg, 500 mg

7.5 mg/kg/dose by mouth, two times daily

Maximum: 500 mg/dose

Penicillin-allergic (life-threatening) or suspected atypical pneumonia:

Option #2: Azithromycin

Tablets: 250 mg, 500 mg

10 mg/kg/day by mouth once, on day 1 (maximum: 500 mg), followed by 5 mg/kg/day by mouth daily, on days 2 to 5 (maximum: 250 mg)

Acute otitis media

(AOM) [9]

Amoxicillin

Capsules: 250 mg, 500 mg

37.5–45 mg/kg/dose by mouth, two times daily

Maximum: 500 mg/dose

Consider rounding dose to the nearest capsule size

<2 years old: 10 days ≥2 years old: 5 days

Second line: Amoxicillin/Clavulanate

Tablets: 500/125 mg, 875/125 mg

Dose based on amoxicillin component

37.5–45 mg/kg/dose by mouth, two times daily

Maximum: 875 mg/dose

Consider rounding dose to the nearest quarter, half, or full tablet

Penicillin-allergic (non-life-threatening)

Cefprozil OR Cefuroxime

Tablets: 250 mg, 500 mg

15 mg/kg/dose by mouth, two times daily

Maximum: 500 mg

Consider rounding dose to nearest half or full tablet

Penicillin-allergic (life-threatening):

Option #1: Clarithromycin

Tablets: 250 mg, 500 mg

7.5 mg/kg/dose by mouth, two times daily

Maximum: 500 mg/dose

Penicillin-allergic (life-threatening):

Option #2: Azithromycin

Tablets: 250 mg, 500 mg

10 mg/kg/day by mouth once, on day 1 (maximum: 500 mg), followed by 5 mg/kg/day by mouth daily, on days 2 to 5 (maximum: 250 mg)

5 days

Group A

streptococcal (GAS)

pharyngitis [10]

Penicillin VK

Tablets: 300 mg

<27 kg: 300 mg by mouth, two or three times daily ≥27 kg: 600 mg by mouth, two or three times daily

10 days

Amoxicillin

Capsules: 250 mg, 500 mg

50 mg/kg/dose by mouth once daily (can also be divided for a twice daily dose) Maximum: 1000 mg/day

Consider rounding dose to nearest capsule size

Penicillin-allergic (non-life-threatening):

Cephalexin

Tablets: 250 mg, 500 mg

20 mg/kg/dose by mouth, two times daily

Maximum: 500 mg/dose

Consider rounding dose to nearest half or full tablet

Penicillin-allergic (life-threatening):

Option #1:

Clarithromycin Tablets: 250 mg

7.5 mg/kg/dose by mouth, two times daily

Maximum: 250 mg/dose

Penicillin-allergic (life-threatening)

Option #2:

Azithromycin Tablets: 250 mg, 500 mg

12 mg/kg/dose by mouth daily

Maximum: 500 mg/dose

5 days

Urinary tract infection

(UTI)

≥ 3 months [11]

(empiric therapy awaiting urine culture result)

Cephalexin

Tablets: 250 mg, 500 mg

15–20 mg/kg/dose by mouth, three times daily

Maximum: 500 mg/dose

Consider rounding dose to nearest half or full tablet

7 days

Co-trimoxazole (trimethoprim/sulfamethoxazole)

Tablets: 80/400 mg, 160/800 mg

Dose based on trimethoprim component

4–6 mg/kg/dose by mouth, two times daily

Maximum:160 mg of trimethoprim/dose

Consider rounding dose to nearest quarter, half, or full tablet

Uncomplicated non-febrile UTI: 3 days

Uncomplicated febrile UTI: 7-10 days

Cefixime

Tablet: 400 mg

8 mg/kg/dose by mouth once daily

Maximum: 400 mg/dose

Consider rounding dose to nearest quarter, half, or full tablet

Amoxicillin/Clavulanate

Tablets: 500/125 mg, 875/125 mg

Dose based on amoxicillin component

<35 kg: 15-20 mg/kg/dose by mouth, three times daily (Maximum: 500 mg/dose)

Consider rounding dose to nearest quarter, half, or full tablet ≥35 kg: 500 mg/125 mg by mouth, three times daily

OR 875 mg/125 mg by mouth, two times daily

Ciprofloxacin

Tablets: 250 mg, 500 mg, 750 mg

15 mg/kg/dose by mouth, two times daily

Maximum: 750 mg/dose

Table 1. Recommended antibiotic doses and durations for common paediatric infections is also available as a supplementary file.

5. Providers should prescribe an antibiotic rounded to a dose that can be dispensed in tablet or capsule form whenever possible and appropriate. 

Certain tablets can be split or crushed to ensure the appropriate dose is administered. Pharmacists may instruct families to mix a crushed tablet with milk, juice, other cold liquid or with pudding or ice cream (depending on the medication) to mask the taste.  

To aid pharmacists with resource-sensitive dispensing, prescriptions must call for dosing that aligns with standard tablet sizes. For greater clarity, consider writing specifically on each prescription to “provide as quarter, half, or full tablets if oral liquids are not available”. 

Certain capsules can be opened, and the medication dissolved in a liquid or mixed with a particular food, before administration. The guidance to parents regarding the manipulation of capsules should be provided by pharmacists.    

6. Children and youth should be encouraged to learn how to swallow pills when they are old enough and readily able to do so. Several effective online resources are available to help patients learn this valuable skill. By directing parents to administer tablets or capsules when appropriate, prescribers and pharmacists help reserve the limited supply of liquid formulations for the patients who most need them.

7.  While rolling shortages are expected to continue, it is important for physicians to be aware of the availability of commonly prescribed medications in their community. It is challenging for pharmacists to contact physicians when a prescribed medication is not available. This additional step delays care and demands extra time from all care providers. 

Acknowledgements

This practice point was reviewed by the CPS Infectious Disease and Immunization Committee.


CANADIAN PAEDIATRIC SOCIETY DRUG THERAPY AND HAZARDOUS SUBSTANCES COMMITTEE (2022-2023)

Members: Yaron Finkelstein MD, Shinya Ito MD, Geert ‘t Jong MD (Chair), Derek McCreath BScPharm, Tom McLaughlin MD, Charlotte Moore Hepburn MD (Board Representative), Eva Slight-Simcoe MD (Resident Member)

Liaison: Michael J. Rieder MD PhD (Canadian Society of Pharmacology and Therapeutics)

Principal authors: Derek McCreath BScPharm, Geert ‘t Jong MD PhD, Yaron Finkelstein MD, Charlotte Moore Hepburn MD


References

  1. Health Canada. Drug shortages in Canada: Regulations and guidance. Date last modified September 1, 2022 (Accessed November 25, 2022).
  2. Drug Shortages Canada. Summary Report (Accessed November 25, 2022).
  3. Wagner T, Burns JL. Anti-inflammatory properties of macrolides. Pediatr Infect Dis J 2007;26(1):75-76. doi: 10.1097/01.inf.0000253037.90204.9f.
  4. Mosquera R, Gomez-Rubio AM, Harris T, et al. Anti-inflammatory effect of prophylactic macrolides on children with chronic lung disease: A protocol for a double-blinded randomised controlled trial. BMJ Open 2016;6(9):e012060. doi: 10.1136/bmjopen-2016-012060.
  5. Welk B, McArthur E, Zorzi AP. Association of virtual care expansion with environmental sustainability and reduced patient costs during the COVID-19 pandemic in Ontario, Canada. JAMA Netw Open 2022;5(10)e2237545. doi: 10.1001/jamanetworkopen.2022.37545.
  6. Goldbloom EB, Buba M, Bhatt M, Sungtharalingam S, King WJ. Innovative virtual care delivery in a Canadian paediatric tertiary-care centre. Paediatr Child Health 2022;27(Suppl 1):S9-S14. doi: 10.1093/pch/pxab104.
  7. Le Saux N, Robinson JL; CPS Infectious Diseases and Immunization Committee. Uncomplicated pneumonia in healthy Canadian children and youth: Practice points for management.
  8. Li Q, Zhou Q, Florez ID, et al. Short-course vs long-course antibiotic therapy for children with nonsevere community-acquired pneumonia: A systematic review and meta-analysis. JAMA Pediatr 2022. doi: 10.1001/jamapediatrics.2022.4123. Epub ahead of print.
  9. Le Saux N, Robinson JL; CPS Infectious Diseases and Immunization Committee. Management of acute otitis media in children six months of age and older.
  10. Sauve L, Forrester AM, Top KA; CPS Infectious Diseases and Immunization Committee. Group A streptococcal (GAS) pharyngitis: A practical guide to diagnosis and treatment.
  11. Robinson JL, Finlay JC, Lang ME, Bortolussi R; CPS Infectious Diseases and Immunization Committee. Urinary tract infection in infants and children: Diagnosis and management.

Disclaimer: The recommendations in this position statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate. Internet addresses are current at time of publication.

Last updated: Nov 24, 2023